| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,100,000 |
| Market
Cap: |
3.42(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.06 - $59.36 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
762 |
174,026 |
230,439 |
439,223 |
| Total Sell Value |
$28,902 |
$7,333,652 |
$10,290,600 |
$18,933,326 |
| Total People Sold |
1 |
8 |
9 |
10 |
| Total Sell Transactions |
2 |
13 |
19 |
40 |
| End Date |
2025-03-16 |
2024-12-13 |
2024-06-14 |
2023-06-15 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dunsire Deborah |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
30,815 |
|
- |
|
| Suliman Shehnaaz |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
25,940 |
|
- |
|
| Welch Daniel G |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
32,690 |
|
- |
|
| Narachi Michael |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
32,690 |
|
- |
|
| Sanders Corazon (corsee) D. |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
17,749 |
|
- |
|
| Ray Amrit |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
23,365 |
|
- |
|
| Fust Matthew K |
|
– • – |
2025-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,740 |
25,945 |
|
- |
|
| Crombez Eric |
EVP and Chief Medical Officer |
• – – |
2025-05-05 |
4 |
S |
$39.24 |
$20,405 |
D/D |
(520) |
71,530 |
|
4% |
|
| Crombez Eric |
EVP and Chief Medical Officer |
• – – |
2025-04-21 |
4 |
S |
$35.11 |
$8,497 |
D/D |
(242) |
71,680 |
|
-6% |
|
| Horn Howard |
Chief Financial Officer |
• – – |
2025-03-06 |
4 |
S |
$40.40 |
$72,114 |
D/D |
(1,785) |
106,169 |
|
6% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2025-03-03 |
4 |
D |
$42.92 |
$21,803 |
D/D |
(508) |
264,730 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$253,779 |
D/D |
(6,028) |
265,238 |
|
9% |
|
| Pinion John Richard |
See Remarks |
• – – |
2025-03-03 |
4 |
D |
$42.92 |
$1,331 |
D/D |
(31) |
108,428 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$607,882 |
D/D |
(14,439) |
107,766 |
|
9% |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2025-03-03 |
4 |
D |
$42.92 |
$6,052 |
D/D |
(141) |
50,124 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$40,711 |
D/D |
(967) |
50,265 |
|
9% |
|
| Huang Dennis Karl |
See Remarks |
• – – |
2025-03-03 |
4 |
D |
$42.92 |
$57,856 |
D/D |
(1,348) |
114,591 |
|
- |
|
| Parschauer Karah Herdman |
EVP and Chief Legal Officer |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$540,817 |
D/D |
(12,846) |
75,287 |
|
9% |
|
| Kakkis Emil D |
President & CEO |
• • – |
2025-03-03 |
4 |
S |
$42.10 |
$3,091,571 |
D/D |
(73,434) |
641,731 |
|
9% |
|
| Crombez Eric |
EVP and Chief Medical Officer |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$376,585 |
D/D |
(8,945) |
71,922 |
|
9% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2025-03-03 |
4 |
S |
$42.10 |
$635,836 |
D/D |
(15,103) |
87,855 |
|
9% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
18,443 |
271,266 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,937 |
122,205 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,392 |
51,232 |
|
- |
|
| Huang Dennis Karl |
See Remarks |
• – – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,937 |
115,939 |
|
- |
|
628 Records found
|
|
Page 1 of 26 |
|
|
0.38 (1.01%) 
